Literature DB >> 28894304

Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV.

M Aghourian1,2,3, C Legault-Denis1,2,3, J-P Soucy2,4,5, P Rosa-Neto2,3,4, S Gauthier3,4, A Kostikov2,4, P Gravel2, M-A Bédard1,2,3.   

Abstract

18F-fluoroethoxybenzovesamicol (FEOBV) is a new PET radiotracer that binds to the vesicular acetylcholine transporter. In both animals and healthy humans, FEOBV was found sensitive and reliable to characterize presynaptic cholinergic nerve terminals in the brain. It has been used here for we believe the first time in patients with Alzheimer's disease (AD) to quantify brain cholinergic losses. The sample included 12 participants evenly divided in healthy subjects and patients with AD, all assessed with the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) cognitive scales. Every participant underwent three consecutive PET imaging sessions with (1) the FEOBV as a tracer of the cholinergic terminals, (2) the 18F-NAV4694 (NAV) as an amyloid-beta tracer, and (3) the 18F-Fluorodeoxyglucose (FDG) as a brain metabolism agent. Standardized uptake value ratios (SUVRs) were computed for each tracer, and compared between the two groups using voxel wise t-tests. Correlations were also computed between each tracer and the cognitive scales, as well as between FEOBV and the two other radiotracers. Results showed major reductions of FEOBV uptake in multiple cortical areas that were evident in each AD subject, and in the AD group as a whole when compared to the control group. FDG and NAV were also able to distinguish the two groups, but with lower sensitivity than FEOBV. FEOBV uptake values were positively correlated with FDG in numerous cortical areas, and negatively correlated with NAV in some restricted areas. The MMSE and MoCA cognitive scales were found to correlate significantly with FEOBV and with FDG, but not with NAV. We concluded that PET imaging with FEOBV is more sensitive than either FDG or NAV to distinguish AD patients from control subjects, and may be useful to quantify disease severity. FEOBV can be used to assess cholinergic degeneration in human, and may represent an excellent biomarker for AD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28894304     DOI: 10.1038/mp.2017.183

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  31 in total

1.  Kinetic modeling of [18 F]VAT, a novel radioligand for positron emission tomography imaging vesicular acetylcholine transporter in non-human primate brain.

Authors:  Hongjun Jin; Xuyi Yue; Hui Liu; Junbin Han; Hubert Flores; Yi Su; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  J Neurochem       Date:  2018-03-25       Impact factor: 5.372

2.  The impact of dopamine D2-like agonist/antagonist on [18F]VAT PET measurement of VAChT in the brain of nonhuman primates.

Authors:  Hui Liu; Zonghua Luo; Jiwei Gu; Yi Su; Hubert Flores; Stanley M Parsons; Yun Zhou; Joel S Perlmutter; Zhude Tu
Journal:  Eur J Pharm Sci       Date:  2019-11-15       Impact factor: 4.384

Review 3.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

4.  Radiosynthesis and evaluation of a fluorine-18 labeled radioligand targeting vesicular acetylcholine transporter.

Authors:  Xuyi Yue; Zonghua Luo; Hui Liu; Kota Kaneshige; Stanley M Parsons; Joel S Perlmutter; Zhude Tu
Journal:  Bioorg Med Chem Lett       Date:  2018-09-24       Impact factor: 2.823

5.  Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study.

Authors:  Roger L Albin; Nicolaas I Bohnen; Martijn L T M Muller; William T Dauer; Martin Sarter; Kirk A Frey; Robert A Koeppe
Journal:  J Comp Neurol       Date:  2018-10-19       Impact factor: 3.215

6.  Longitudinal Alzheimer's Degeneration Reflects the Spatial Topography of Cholinergic Basal Forebrain Projections.

Authors:  Taylor W Schmitz; Marieke Mur; Meghmik Aghourian; Marc-Andre Bedard; R Nathan Spreng
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

7.  Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.

Authors:  Sygrid van der Zee; Martijn L T M Müller; Prabesh Kanel; Teus van Laar; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2020-11-02       Impact factor: 10.338

8.  Regional cerebral cholinergic nerve terminal integrity and cardinal motor features in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Robert A Koeppe; Carlos A Sanchez-Catasus; Kirk A Frey; Peter Scott; Gregory M Constantine; Roger L Albin; Martijn L T M Müller
Journal:  Brain Commun       Date:  2021-05-22

9.  Modulation of arousal and sleep/wake architecture by M1 PAM VU0453595 across young and aged rodents and nonhuman primates.

Authors:  Robert W Gould; Jason K Russell; Michael T Nedelcovych; Michael Bubser; Anna L Blobaum; Thomas M Bridges; Paul A Newhouse; Craig W Lindsley; P Jeffrey Conn; Michael A Nader; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2020-08-31       Impact factor: 7.853

Review 10.  Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.

Authors:  Martin Sarter; Cassandra Avila; Aaron Kucinski; Eryn Donovan
Journal:  Mov Disord       Date:  2021-02-22       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.